Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
$1.15
+1.6%
$1.25
$0.85
$4.40
$36.85M0.2131,344 shs6,065 shs
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$3.34
+8.1%
$4.66
$1.04
$7.25
$49.97M-0.39867,964 shs26,913 shs
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
$1.95
$2.17
$1.50
$6.48
$13.83M1.387,484 shsN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
$8.16
$8.02
$0.83
$8.35
$564.92M0.35992,630 shsN/A
Soligenix Inc. stock logo
SNGX
Soligenix
$1.27
+1.6%
$1.73
$1.09
$9.78
$4.14M1.87429,116 shs567,755 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
+0.58%-2.47%-9.88%+1.49%-61.42%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
+0.65%-9.38%-47.54%-23.33%+107.38%
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
0.00%0.00%0.00%0.00%0.00%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
0.00%0.00%-1.69%+374.42%+385.71%
Soligenix Inc. stock logo
SNGX
Soligenix
+2.46%-0.79%-32.58%-34.18%-83.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
1.4683 of 5 stars
0.05.00.00.01.73.30.0
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.5943 of 5 stars
0.03.00.00.02.21.70.0
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/AN/AN/AN/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
1.5577 of 5 stars
2.15.00.00.00.03.30.0
Soligenix Inc. stock logo
SNGX
Soligenix
1.6797 of 5 stars
0.05.00.00.03.10.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
0.00
N/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.00
N/AN/AN/A
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
0.00
N/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
2.29
Hold$8.504.17% Upside
Soligenix Inc. stock logo
SNGX
Soligenix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SNGX, FWP, CPIX, RGLS, and AKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$9.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$7.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$28.00 ➝ $11.00
4/30/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$8.00 ➝ $7.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A$0.84 per shareN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
$37.87M1.32$0.28 per share11.94$1.61 per share2.07
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/AN/AN/AN/A$10.09 per shareN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/A$1.17 per shareN/A
Soligenix Inc. stock logo
SNGX
Soligenix
$120K34.50N/AN/A$1.64 per share0.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
-$19.79MN/A0.00N/AN/A-213.59%-65.60%8/18/2025 (Estimated)
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
-$6.48M-$0.25N/AN/A-7.98%6.92%2.33%8/5/2025 (Estimated)
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
-$1.89MN/A0.00N/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%8/6/2025 (Estimated)
Soligenix Inc. stock logo
SNGX
Soligenix
-$8.27M-$4.29N/AN/AN/AN/A-223.89%-103.50%8/8/2025 (Estimated)

Latest SNGX, FWP, CPIX, RGLS, and AKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Soligenix Inc. stock logo
SNGX
Soligenix
-$0.67-$1.06-$0.39-$1.06N/AN/A
5/8/2025Q1 2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.29-$0.15+$0.14-$0.15N/AN/A
5/6/2025Q1 2025
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/A$0.15N/A$0.08N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/A
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
N/AN/AN/AN/AN/A
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/AN/A
Soligenix Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/A
0.16
0.16
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
0.18
1.25
1.09
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
N/A
18.43
N/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/A
16.31
16.31
Soligenix Inc. stock logo
SNGX
Soligenix
N/A
1.85
1.85

Institutional Ownership

CompanyInstitutional Ownership
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
5.06%
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
15.51%
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
12.57%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
92.38%
Soligenix Inc. stock logo
SNGX
Soligenix
3.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
932.18 million19.92 millionNot Optionable
Cumberland Pharmaceuticals Inc. stock logo
CPIX
Cumberland Pharmaceuticals
8014.96 million8.25 millionOptionable
Forward Pharma A/S stock logo
FWP
Forward Pharma A/S
47.09 million2.02 millionNot Optionable
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
3069.23 million66.22 millionOptionable
Soligenix Inc. stock logo
SNGX
Soligenix
203.26 million3.16 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akari Therapeutics stock logo

Akari Therapeutics NASDAQ:AKTX

$1.14 +0.02 (+1.64%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Cumberland Pharmaceuticals stock logo

Cumberland Pharmaceuticals NASDAQ:CPIX

$3.34 +0.25 (+8.09%)
Closing price 04:00 PM Eastern
Extended Trading
$3.34 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Forward Pharma A/S stock logo

Forward Pharma A/S NASDAQ:FWP

Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.

Regulus Therapeutics stock logo

Regulus Therapeutics NASDAQ:RGLS

$8.16 0.00 (0.00%)
As of 06/25/2025

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Soligenix stock logo

Soligenix NASDAQ:SNGX

$1.27 +0.02 (+1.60%)
Closing price 04:00 PM Eastern
Extended Trading
$1.26 -0.01 (-0.79%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.